In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
Diabetes Connections | Type 1 Diabetes
Release Date: 03/24/2026
What's Next for Dexcom? G8, New Research & Your Questions with Jessica Castle, VP Global Medical Affairs
Diabetes Connections | Type 1 Diabetes
On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD international conference. I’m asking your questions about longer sensor wear for kids, changes to adhesive, what’s going on with the G8 and more. Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin. This podcast is not meant at medical advice, if you have those types of questions, please ask...
info_outline
In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more!
Diabetes Connections | Type 1 Diabetes
This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2. Plus, new data on Lilly’s daily GLP-1...
info_outline
Moving Diabetes Solutions Forward: Beyond Type 1’s Innovation Accelerator
Diabetes Connections | Type 1 Diabetes
On this bonus episode of diabetes connections, we’re talking about the Beyond Barriers Innovation Accelerator. This is a project from Beyond Type 1 which is investing in community-based organizations and entrepreneurs working to close those gaps. We’ll hear about some really interesting projects from comic books for kids to apps for first responders and programs to help with cost… And we’ll zoom out: eleven years after Beyond Type 1 launched, what is the organization today—and how is it trying to make sure more people with diabetes have the opportunity not just to survive, but to...
info_outline
Sharing T1D With the World: Shannon Boggs on Parenting, Independence & Community
Diabetes Connections | Type 1 Diabetes
Shannon Boggs’ daughter Raelynn, was still doing backflips at gymnastics just days before she landed in the ICU in DKA and was diagnosed with type 1 diabetes. Four years later, things look very different. Raelynn is starting middle school, taking on more of her own diabetes management, going to regular sleepaway camp, and even sharing her life with type 1 online — with hundreds of thousands of people following along. Shannon and I talk about that sometimes-scary balance between independence and diabetes management, why finding community changed everything for their family, and how she...
info_outline
In the News.. ADA Boycott, new patch pumps, endometriosis and type 2 risk, Zverev wins US Open with T1D, and more!
Diabetes Connections | Type 1 Diabetes
On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Want to let you know about a webinar I’m doing with Abbott later this month. That’s Sept...
info_outline
Eversense 365 + twiist: New Data & What’s Next for the Implantable CGM
Diabetes Connections | Type 1 Diabetes
This week on Diabetes Connections.. Now that Eversense 365-day has been out in the real world and is working with the twiist automated insulin delivery system, we’re starting to get a much better picture of what that combination can actually do. This week, Dr. Fran Kaufman is back with new data on Eversense 365, including some impressive results from people using it with twiist. We’ll talk about what they’re learning, who’s using the year-long sensor, and what may be coming next. And that next step is really interesting: a sensor with its own battery that could work even when the...
info_outline
Type 1 Diabetes Screening Has Changed. What You Need to Know Now (Bonus episode)
Diabetes Connections | Type 1 Diabetes
A few years ago, when we talked about screening for type 1 diabetes, it still felt a little bit like we were talking about the future. That future may be arriving faster than we realize. Dr. Bryce Nelson is back on the show. After years as a pediatric endocrinologist, he’s now working specifically in autoimmune type 1 diabetes with Sanofi. We talk about how much has changed with screening, what we’re learning about who’s at risk, and the big question: how close are we to screening becoming a routine part of healthcare? And Jenny Hoffman shares what this looks like for a family...
info_outline
In the News... Mounjaro update, CGM Medicare coverage shift, Metformin and aging study, Dolly Parton T1D connection and more!
Diabetes Connections | Type 1 Diabetes
On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don’t use insulin and a new study about using CGM when you don’t have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! ...
info_outline
Live Free with T1D: How to Stop Diabetes Stress From Shrinking Your Life, with Dr. Mark Heyman
Diabetes Connections | Type 1 Diabetes
We’re taught about what to do when blood sugar goes high or low, but almost nothing about what to do when diabetes burnout, anxiety, or fear takes over. My guest – Dr. Mark Heyman says the biggest thing holding you back with type 1 diabetes may not be your blood sugar — but the stress of managing it. Mark lives with type 1 and his new book, Live Free with T1D, offers what he calls an “operating system” for the emotional side of diabetes — practical tools for handling the uncomfortable moments without letting them make your world smaller. This podcast is not intended as medical...
info_outline
In the News.. new weekly basal, retatrutide lawsuits, childhood T1D studies, run for T1D research and more!
Diabetes Connections | Type 1 Diabetes
On this episode of Diabetes Connections In the News… A new basal insulin is available, researchers are working on a “cloak” designed to protect transplanted insulin-producing cells, Retatrutide isn’t even approved and it’s already the subject of lawsuits, tandem moves to pharmacy and more! Check out all of Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by...
info_outlineIt's In the News, a look at the top headlines and stories in the diabetes community.
This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more!
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
transcript with links:
Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Who’s in Vegas? I’ll see you there at the Breakthrough T1D summit this weekend.
And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more.
Okay.. our top story this week:
XX
Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication.
It’s one of the leading causes of vision loss in the US and many other western countries.
These researchers now say a clinical trial is the next step.
https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/
XX
new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes.
Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes.
However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.
XX
Researchers in Japan say they’ve developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor.
The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice’s blood sugar was reduced to near-normal levels.
Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed.
https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests
XX
Lilly says it’s next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight.
Retatrutide also met the study’s second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight.
The company was also “very pleased” with the relatively low discontinuation rates due to side effects, which were up to 5%, he added.
But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year.
Still, retatrutide’s A1C reduction doesn’t appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients.
Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person’s appetite and satisfaction with food than other treatments.
XX
The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It’s about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott.
MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0.
MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes.
XX
Lots of new out of the recent ATTD conference.. some headlines:
New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year.
--
The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells.
--
Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.
Researchers noted that the body’s response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows.
--
More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.
Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.
Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85.
https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026
XX
Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it’s the world’s first fully closed loop commercial launch.
CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife’s (formerly Ypsomed Diabetes Care’s) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device.
https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/
XX
Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes.
The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy.
Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027.
Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.
https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/
XX
Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.